500674 Stoklara Genel Bakış Sanofi India Limited, Hindistan, Singapur ve uluslararası alanda ilaç ve eczacılık ürünleri üretmekte ve ticaretini yapmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Sanofi India Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Sanofi India Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı ₹6,102.90 52 Haftanın En Yüksek Seviyesi ₹10,526.05 52 Haftanın En Düşük Seviyesi ₹5,850.55 Beta 0.30 1 Aylık Değişim -4.07% 3 Aylık Değişim -11.39% 1 Yıllık Değişim -26.95% 3 Yıllık Değişim -19.56% 5 Yıllık Değişim -10.42% Halka arzdan bu yana değişim 1,643.69%
Son Haberler & Güncellemeler
Third quarter 2024 earnings released: EPS: ₹35.69 (vs ₹65.95 in 3Q 2023) Nov 08
Sanofi India Limited to Report Q3, 2024 Results on Nov 07, 2024 Oct 17
Sanofi India Limited Announces Resignation of Radhika Shah as Head of Legal and Company Secretary Sep 04 Sanofi India Limited Announces Cessation of Cyrus Aibara as Senior Director Diabetes Aug 30
Price target decreased by 9.1% to ₹8,501 Aug 02
New major risk - Revenue and earnings growth Aug 01 Daha fazla güncelleme görün
Third quarter 2024 earnings released: EPS: ₹35.69 (vs ₹65.95 in 3Q 2023) Nov 08
Sanofi India Limited to Report Q3, 2024 Results on Nov 07, 2024 Oct 17
Sanofi India Limited Announces Resignation of Radhika Shah as Head of Legal and Company Secretary Sep 04 Sanofi India Limited Announces Cessation of Cyrus Aibara as Senior Director Diabetes Aug 30
Price target decreased by 9.1% to ₹8,501 Aug 02
New major risk - Revenue and earnings growth Aug 01
Second quarter 2024 earnings released: EPS: ₹29.61 (vs ₹53.37 in 2Q 2023) Jul 27
Sanofi India Limited Announces Resignation of Nitin Joshi, Head - Supply Chain, Effective 31 July 2024 Jul 18
Sanofi India Limited to Report Q2, 2024 Results on Jul 26, 2024 Jul 09
Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024 Jul 04
Less than half of directors are independent Jul 01
Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head Diabetes, Effective July 1, 2024 Jun 24
New major risk - Share price stability Jun 13
Investor sentiment improves as stock rises 17% Jun 11 Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead
First quarter 2024 earnings released: EPS: ₹59.31 (vs ₹82.67 in 1Q 2023) May 14
Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility Apr 16
Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee Mar 29
Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director, Member of the Nomination and Remuneration Committee Mar 28
Final dividend of ₹117 announced Mar 08
Upcoming dividend of ₹50.00 per share Feb 29
Price target increased by 8.8% to ₹9,371 Feb 28
Full year 2023 earnings released: EPS: ₹262 (vs ₹269 in FY 2022) Feb 24
Sanofi India Limited, Annual General Meeting, May 14, 2024 Feb 24 Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024
Sanofi India Limited to Report Q4, 2023 Results on Feb 23, 2024 Jan 25
Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024 Jan 10
Price target increased by 12% to ₹8,392 Nov 17
Third quarter 2023 earnings released: EPS: ₹65.95 (vs ₹56.84 in 3Q 2022) Nov 10 Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director
Sanofi India Limited to Report Q3, 2023 Results on Nov 08, 2023 Oct 20
Sanofi India Limited Appoints Surabhi Kaul as India People Director and Will Be Part of the Senior Management Personnel Oct 17
Less than half of directors are independent Oct 06
Sanofi India Limited Announces Executive Changes Sep 27
Sanofi India Limited Announces Resignation of Vinita Korti Patil as Senior Legal Director - South Asia, Effective 7 December 2023 Sep 15
Second quarter 2023 earnings released: EPS: ₹53.37 (vs ₹52.28 in 2Q 2022) Aug 11
Sanofi India Limited Announces Resignation of Gaurav Bahadur as People Director Aug 04
Less than half of directors are independent Aug 03
Sanofi India Limited to Report Q2, 2023 Results on Aug 10, 2023 Jul 26
Sanofi India Limited Announces Resignation of Annapurna Das as Non-Executive Director and Member of the Audit Committee, Effective 31 July 2023 Jul 22
Upcoming dividend of ₹377 per share at 3.3% yield Apr 21
Price target decreased by 7.9% to ₹6,604 Mar 01
Price target decreased by 8.5% to ₹6,986 Feb 24
Sanofi India Limited to Report Q4, 2022 Results on Feb 23, 2023 Feb 08
High number of new directors Dec 02
Third quarter 2022 earnings released: EPS: ₹56.84 (vs ₹230 in 3Q 2021) Nov 06
Sanofi India Limited Announces Change in Directorate Nov 04
Sanofi India Limited to Report Q3, 2022 Results on Nov 03, 2022 Oct 22
Upcoming dividend of ₹193 per share Jul 29
Price target decreased to ₹7,800 Jul 28
Second quarter 2022 earnings released: EPS: ₹52.28 (vs ₹77.42 in 2Q 2021) Jul 27
Sanofi India Limited Approves One-Time Special Interim Dividend, Payable on August 22, 2022 Jul 22
Sanofi India Limited to Report Q2, 2022 Results on Jul 26, 2022 Jul 07
First quarter 2022 earnings released: EPS: ₹104 (vs ₹63.35 in 1Q 2021) Apr 28
Less than half of directors are independent Apr 27
Sanofi India Appoints Rodolfo Hrosz as Managing Director Apr 19
Sanofi India Limited to Report Q1, 2022 Results on Apr 26, 2022 Apr 09
Upcoming dividend of ₹490 per share Apr 07
Full year 2021 earnings released: EPS: ₹410 (vs ₹207 in FY 2020) Apr 03 Sanofi India Limited Proposes Final Dividend for the Financial Year Ended December 31, 2021, Payable on or After May 4, 2022
Sanofi India Limited, Annual General Meeting, Apr 26, 2022 Feb 25 Sanofi India Limited Approves Final Dividend for the Year Ended 31 December 2021
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Sanofi India Limited to Report Q4, 2021 Results on Feb 23, 2022 Feb 08
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 29
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 29
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 29
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 29
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 29
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 29
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 28
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 27
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 27
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 27
Non-Executive Director Cyril Grandchamp-Desraux has left the company Nov 27 Hissedar Getirileri 500674 IN Pharmaceuticals IN Pazar 7D 0.1% 3.0% 1.8% 1Y -27.0% 36.5% 18.0%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 500674 geçen yıl % 36.5 oranında getiri sağlayan Indian Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: 500674 geçen yıl % 18 oranında getiri sağlayan Indian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 500674's price volatile compared to industry and market? 500674 volatility 500674 Average Weekly Movement 2.9% Pharmaceuticals Industry Average Movement 5.9% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
İstikrarlı Hisse Senedi Fiyatı: 500674 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 500674 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Sanofi India Limited, Hindistan, Singapur ve uluslararası alanda ilaç ve farmasötik ürünler üretmekte ve ticaretini yapmaktadır. Şirket, Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra ve Avil markaları altında diyabet, kardiyoloji, tromboz, enfeksiyonlar, merkezi sinir sistemi, anti-enfektifler, epilepsi, alerji ve vitaminler ve mineraller ve takviyeler gibi çeşitli terapötik alanlarda farmasötik ürünler ve ayrıca ağrı bakımı ve beslenme sağlığı sağlamaktadır. Ayrıca ürünlerini yaklaşık 35 ülkeye ihraç etmektedir.
Daha fazla göster Sanofi India Limited Temel Bilgiler Özeti Sanofi India'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 500674 temel i̇stati̇sti̇kler Piyasa değeri ₹140.55b Kazançlar(TTM ) ₹5.30b Gelir(TTM ) ₹28.23b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 500674 gelir tablosu (TTM ) Gelir ₹28.23b Gelir Maliyeti ₹12.14b Brüt Kâr ₹16.09b Diğer Giderler ₹10.78b Kazançlar ₹5.30b
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) 230.30 Brüt Marj 56.99% Net Kâr Marjı 18.79% Borç/Özkaynak Oranı 3.2%
500674 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün Temettüler
2.7% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/02 09:26 Gün Sonu Hisse Fiyatı 2025/01/02 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Sanofi India Limited 14 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Sarabjit Nangra Angel Broking Private Limited Rohit Bhat Batlivala & Karani Securities India Pvt. Ltd. Ranjit Kapadia Centrum Broking Limited
Göster 11 daha fazla analist 
